Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: An EORTC-STBSG study

British Journal of Cancer

Volumn 107, Issue 4, 2012, Pages 639-645

  Sleijfer, S ^a   Gorlia, T ^b   Lamers, C ^a   Burger, H ^a   Blay, J Y ^c   Le Cesne, A ^d   Scurr, M ^e   Collin, F ^f   Pandite, L ^g   Marreaud, S ^b   Hohenberger, P ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f CENTRE GEORGES FRANÇOIS LECLERC   (France)

^g GLAXOSMITHKLINE   (United States)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

cytokines; pazopanib; prognosis; soft tissue sarcomas

Indexed keywords

BASIC NERVE GROWTH FACTOR; COLONY STIMULATING FACTOR 1; CYTOKINE; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P40; INTERLEUKIN 1ALPHA; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 3; PAZOPANIB; PLACENTAL DERIVED GROWTH FACTOR; PLACENTAL GROWTH FACTOR; SCATTER FACTOR; SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; THERAPY EFFECT;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-12 SUBUNIT P40; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PREGNANCY PROTEINS; PYRIMIDINES; REPRESSOR PROTEINS; SARCOMA; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84864882447     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.328     Document Type: Article

References (20)

1. Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, Notari KH, Peach M, Hei YJ, Patterson SD (2010) Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 95: 5018-5027
2. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A (2009) Efficacy and safety of trabectidin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27: 4188-4196
3. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marme D (2005) Soluble markers for the assessment of biological activity with PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16: 558-565
4. Ebos JM, Lee CR, Christensen JG, Mutsaerts AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumorindependent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104: 17069-17074
5. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, Schwartz GK, Casper ES (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86: 2034-2037
6. Fischer C, Mazzone M, Jonckx B, Carmeliet P (2008) FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8: 942-956
7. Hamberg P, Verweij J, Sleijfer S (2010) (Pre)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 15: 539-547
8. Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV (2009a) Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small cell lung cancer. J Clin Oncol 28: 193-201
9. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV (2009b) Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small lung cancer. Clin Cancer Res 15: 3600-3609
10. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M (2008) A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3: 386-393
11. Murukesh N, Dive C, Jayson GC (2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 102: 8-18
12. Nikolanikos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV (2010) Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 70: 2171-2179
13. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26: 3743-3748
14. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS (2007) Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 2369-2376
15. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma group (EORTC 62043). J Clin Oncol 27: 3126-3132
16. Sleijfer S, Seynaeve C, Verweij J (2005) Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 10: 833-841
17. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S (2007) The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist 12: 1351-1360
18. Tran HT, Liu Y, Lin Y, Martin A-M, Baker KL, Fritsche HA, Zurita A, Pandite LN, Heymach JV (2010) Use of multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. J Clin Oncol 28 (suppl 15s): abstr 4522
19. Van der Graaf WT, Blay JY, Chawla SP, Kim D, Bui Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji M, Dei Tos AP, Hohenberger P (2011) PALETTE: a randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-an EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 29 (suppl): abstr LBA10002
20. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: a randomised trial. Lancet 364: 1127-1134